Drug intelligence / Profile preview

VIPER-103

Development stage: Preclinical
Lead developer: Vittoria Biotherapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

VIPER-103 is an experimental CAR T-cell therapy developed by viTToria Biotherapeutics. It utilizes chimeric antigen receptor (CAR) T-cells engineered to target a novel B-cell antigen that is highly enriched in cancer and autoimmune diseases. By selectively targeting diseased B-cells, VIPER-103 aims to eliminate pathogenic or malignant cells while sparing healthy B-cells, potentially reducing the risk of immunosuppression associated with traditional B-cell depletion therapies. The program is currently in IND-enabling studies and is being explored for the treatment of B-cell-mediated autoimmune diseases[1].

Beyond the preview

Go deeper on VIPER-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIPER-103.

Explore the full profile